Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed.
Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded research consortium that found no association between a KRAS mutation and risk of the cancer.
Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed.
Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.
Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here.
Most older patients with ovarian cancer may receive care that doesn't measure up to national standards, according to an analysis of a National Cancer Institute (NCI) database and Medicare claims data.
(Updated February 2017) Noting with equal measures of amazement and pride that “Stand-up for Madeline and OCRFA” had its 15th Anniversary on May 16, 2016, John Hansbury lovingly observes that his late wife, the great comedic actress Madeline Kahn “would never do stand-up comedy. She didn’t tell jokes; she was a serious actress. Madeline was … Continued
When Joan Sagan was diagnosed with ovarian cancer in 1999, she was devastated. After more than 20 years working as an oncology nurse, Joan knew how deadly this disease could be. Her sisters, however, knew very little about ovarian cancer. They were surprised to learn that there is no early detection test, unlike breast and … Continued
Robin Cohen was working as an oncology nurse when one of her favorite patients, Sandy Rollman, passed away at age 33 from ovarian cancer. Robin’s work with Sandy and Sandy’s sister Adriana Way made her realize how few resources were available to women with this disease. “It was hard to even find a survivor for … Continued
Laura Stecher founded the Ovarian Cancer Orange County Alliance (OCOCA) in 2003 with friends from her support group. Today, she is a ten-year survivor—and one of only three surviving from their original group of eight. Whenever Laura gets burned out from her work on ovarian cancer, something happens to reenergize her. “I feel like those … Continued
12/21/2010 Available ovarian cancer screening only slightly reduces the number of deaths from the disease, a new study finds. Until more sensitive screening tests can be developed, other strategies, such as better prevention and treatment, are needed to significantly reduce deaths from ovarian cancer, the researchers from Duke University Medical Center said. OCRF sponsored researcher, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
